Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-322 with or without pioglitazone versus placebo for postprandial triglycerides in type 2 diabetes
2007-000486-38Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing SYR-322 monotherapy, SYR-322 + pioglitazone and Placebo (3 arms). Primary endpoint: Change from baseline in postprandial incremental area under the curve for triglycerides. Started Apr 2007; status: completed.
02
Drugs
alogliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-000486-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000486-38.